Patent US4542141A successfully refreshed from Google Patents.
US4542141A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compound having vasodilating, antiaggregating and hypocholesterolemic activities, process for the preparation thereof and pharmaceutical compositions therefrom
Assignee: Edmond Pharma SRL
•
Filing: 1983-10-07
•
Granted: 1985-09-17
•
Expires: 2003-10-07
Abstract
Abstract The compound having formula (I) <IMAGE> (I) is obtained by reacting 1,2-diphenyl-4-[2-phenylsulfinyl)-ethyl]-4-hydroxymethyl-pyrazolidine- 3,5-dione (hydroxymethylsulfinpyrazone) with nicotinic acid, in the presence of activating agents such as DCCD. (I) is endowed with marked vasodilating, antiaggregating and hypocholesterolemic properties.
Inventors
- 👤 Guido Vandoni
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 18:34
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/12; A; A61; A61P; A61P3/00; A61P3/06; A61P7/00; A61P7/02; A61P9/00; A61P9/08; C07D231/00; C07D231/02; C07D231/10; C07D231/14; C07D231/28; C07D231/30; C07D231/32; C07D231/36
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
5 words
1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl]-4-(nicotinoyloxymethyl)-pyrazolidine-3,5-dione, having formula (I): ##STR4##
Claim 2
Dependent Claim
5 words
1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl]-4-(nicotinoyloxymethyl)-pyrazolidine-3,5-dione, having formula (I): ##STR4##
Claim 3
Dependent Claim
28 words
A pharmaceutical composition having vasodilating, antiaggregating and hypocholesterolemic activity which contain an effective amount of compound (I) as the active principle and at least one pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
28 words
A pharmaceutical composition having vasodilating, antiaggregating and hypocholesterolemic activity which contain an effective amount of compound (I) as the active principle and at least one pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
33 words
A pharmaceutical composition as claimed in claim 2 which is in dosage unit form and comprises from 25 to 1000 mg of active ingredient per dosage unit in admixture with a pharmaceutical carrier.
References Cited (Backward Citations)
US2798074A
Cited
US3519640A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-09-16 | 1989-03-18 | 1989-09-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-09-16 | 1993-03-18 | 1993-09-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-09-16 | 1997-03-18 | 1997-09-17 | $7700.00 | Window Closed / Lapsed |